PO.ET05.02 · 实验与分子治疗
通过SSI-4抑制硬脂酰辅酶A去饱和酶1（SCD1）作为非小细胞肺癌的治疗策略
Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
脂质代谢在肺癌的生长、存活和治疗耐药中发挥重要作用。硬脂酰辅酶A去饱和酶1（SCD1）是将饱和脂肪酸（SFA）转化为单不饱和脂肪酸（MUFA）的酶，代表着一种代谢脆弱性，因为癌细胞依赖MUFA进行膜生物合成、内质网稳态以及作为葡萄糖之外的替代能源。SSI-4（又称MTI-301）是一种选择性SCD1抑制剂，目前正处于针对转移性、不可切除或难治性实体瘤的I期临床评估中，但其在非小细胞肺癌（NSCLC）中的活性尚未被表征。为评估NSCLC模型对SCD1阻断的反应，我们在确定的血清条件下对17种人非小细胞肺癌细胞系进行了初步筛选，用100 nM SSI-4处理。细胞活力测定确定了9种有反应的细胞系，剂量反应研究证实IC50值约在0.65至45.5 nM之间。挽救实验显示，添加油酸（一种受SCD1调控的MUFA）可逆转SSI-4介导的生长抑制，从机制上证实这一效应通过SCD1阻断发生。Western blot分析证实，SSI-4处理增加了敏感细胞系中内质网（ER）应激和凋亡的标志物，与脂质稳态破坏一致。相反，无反应的细胞系表现出这些应激通路的极小诱导，尽管接受治疗仍保持活力。软琼脂测定进一步显示，SSI-4减少了有反应细胞系中不依赖锚定的集落形成，表明SCD1抑制在这些NSCLC模型中抑制了一种关键的恶性生长特性。总体而言，这些发现证明SSI-4通过SCD1依赖机制，减少MUFA可用性并激活应激和凋亡信号，选择性抑制NSCLC细胞亚群的增殖。这项工作为后续的体内研究建立了框架，并为探索SCD1抑制作为NSCLC治疗选择有限患者的潜在治疗策略奠定了基础，同时也推进了对SCD1支持肿瘤存活机制的理解。
查看英文原文 English abstract
Lipid metabolism plays an important role in lung cancer growth, survival, and therapeutic resistance. Stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids (SFAs) into monounsaturated fatty acids (MUFAs), represents a metabolic vulnerability since cancer cells depend on MUFAs for membrane biosynthesis, ER homeostasis, and alternative energy to glucose. SSI-4 (a.k.a MTI-301) is a selective SCD1 inhibitor currently in Phase I clinical evaluation for metastatic, unresectable, or refractory solid cancers, but its activity in non-small cell lung cancer (NSCLC) has not yet been characterized. To evaluate how NSCLC models respond to SCD1 blockade, we performed an initial screen of a panel of 17 human non-small cell lung cancer cell lines treated with 100 nM SSI-4 under defined serum conditions. Cell viability assays identified 9 responding cell lines, and dose-response studies confirmed IC50 values ranging from approximately 0.65 to 45.5 nM. Rescue experiments showed that adding oleic acid, an SCD1 regulated MUFA, reversed SSI-4-mediated growth inhibition, confirming mechanistically that this effect occurs through SCD1 blockade. Western blot analysis confirmed that SSI-4 treatment increased markers of endoplasmic reticulum (ER) stress and apoptosis in sensitive lines, consistent with disruption of lipid homeostasis. In contrast, non-responsive lines exhibited minimal induction of these stress pathways and retained viability despite treatment. Soft agar assays further showed that SSI-4 reduced anchorage-independent colony formation in responsive lines, indicating that SCD1 inhibition suppresses a key malignant growth property in these NSCLC models. Collectively, these findings demonstrate that SSI-4 selectively inhibits proliferation in a subset of NSCLC cells through an SCD1-dependent mechanism by reducing MUFA availability and activating stress and apoptotic signaling. This work establishes a framework for subsequent in vivo studies and lays the foundation for exploring SCD1 inhibition as a potential therapeutic strategy for patients with limited treatment options in NSCLC, while also advancing understanding of the mechanisms by which SCD1 supports tumor survival.
利益披露 Disclosure
V. R. Salerno Gonzales, None..
L. Antal, None.